April 15, 2020
On the heels of our spotlight last week looking at the intersection of COVID-19 and HIV, this edition of the Advocates Network features new resources for HIV prevention research and advocacy, work that’s as important today as ever before. Both HIV and COVID-19 are urgent matters of public health, demanding a sustained commitment. Use these tools to stay informed and connected, and scroll down for COVID-19 materials.
PrEP Use Today
- Our infographic, PrEP Initiations By Country World Wide, updates the global number of people initiating PrEP to date. We are monitoring this data particularly closely to see the impact of COVID-19 on PrEP use, so stay tuned for next quarter’s update and all things PrEP at PrEPWatch.org.
- Telling the PrEP Story through Pictures: The Untapped Potential of the PhotoVoice Project – This blog by AVAC and RTI International shares lessons learned from the 3Ps for Prevention (Partners, Perceptions and Pills) study on PrEP use among adolescent girls and young women. The study incorporated a photography project as a way for the young women to document their experience with PrEP. The images gave researchers new insights and empowered the participants.
- This survey on diversifying PrEP delivery models is for partners, implementers and researchers. Please tell us about models of diversified service delivery for PrEP. We want hear about programs and pilots.
Three Weeks of Activism in Action: PEPFAR COPs 2020
Every year, country teams from more than 50 countries work with the US Government’s President’s Emergency Plan for AIDS Relief (PEPFAR) to make plans and set targets for the year ahead. Over three weeks, civil society and advocates are in meeting rooms fighting for better policies and winning important gains. Check out this year’s wins:
- Week 1: An Overview and Wins for West Africa – February 21, 2020
- Week 2: Wins for Zambia and Zimbabwe and More – February 28, 2020
- Week 3: Wins for Malawi, Tanzania and More – March 6, 2020
Px Pulse: Understanding HVTN 702
The latest installment of AVAC’s podcast, Px Pulse, talks about what’s next for HVTN 702 (also known as Uhambo). Data show the vaccine tested is safe, but offers no protection against HIV.
COVID-19 & HIV
AVAC.org’s dedicated page to COVID-19 and HIV provides essential resources to support an advocacy agenda on the combined impact of COVID-19 and HIV.